Clinicopathological and Radiological Study of Egyptian β-Thalassemia Intermedia and β-Thalassemia Major Patients: Relation to Complications and Response to Therapy

REFERENCES

• Galanello R, Origa R. β-Thalassemia. Orphanet J Rare Dis. 2010;5:11–25.
   PubMed Web of Science ®Google Scholar
• ChenW, Zhang X, Shang X, The molecular basis of β-thalassemia intermedia in southern China: genotypic heterogeneity and phenotypic diversity. BMC Med Genet. 2010;11:31–40.
   PubMed Web of Science ®Google Scholar
• Borgna-Pignatti C, Marsella M, Zanforlin N. The natural history of thalassemia intermedia. Ann NY Acad Sci. 2010;1202:214–220.
   PubMed Web of Science ®Google Scholar
• Delvecchio M, Cavallo L. Growth and endocrine function in thalassemia major in childhood and adolescence. J Endocrinol Invest. 2010;33(1):61–68.
   PubMed Web of Science ®Google Scholar
• Taher A, Isma’eel H, Cappellini MD. Thalassemia intermedia: revisited. Blood Cells Mol Dis. 2006;37(1):12–20.
   PubMed Web of Science ®Google Scholar
• Taher AT, Musallam KM, Karimi M, Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. Blood. 2010;115(10):1886–1892.
   PubMed Web of Science ®Google Scholar
• Kattamis A. Treatment of thalassemia with hydroxyurea: an indispensable alternative therapy. J Pediatr Hematol Oncol. 2007; 29(11):729–730.
   PubMedGoogle Scholar
• Cappellini MD, Cohen A, Eleftheriou A, Piga A, Porter J, Taher A. Guidelines for the clinical management of thalassemia, 2nd ed. Thalassaemia International Federation. 2008:121–131.
   Google Scholar
• Weatherall DJ, Clegg JB. The Thalassaemia Syndromes, 4th ed. Oxford: Blackwell Science, 2001.
   Google Scholar
• Ansari SH, Shamsi TS, Siddiqui FJ, Efficacy of hydroxyurea (HU) in reduction of packed red cell transfusion requirement among children having β-thalassemia major: Karachi HU trial (KHUT). J Pediatr Hematol Oncol. 2007;29(11):743–746.
   PubMedGoogle Scholar
• El Rassi F, Cappellini MD, Intai A, Taher A. β-Thalassemia intermedia: An overview. Pediatr Ann. 2008;37(5):322–328.
   PubMed Web of Science ®Google Scholar
• Singer ST, Kuypers FA, Styles L, Vichinsky EP, Foote D, Rosenfeld H. Pulmonary hypertension in thalassemia: association with platelet activation and hypercoagulable state. Am J Hematol. 2006;81(9):670–675.
   PubMed Web of Science ®Google Scholar
• Derchi G, Forni GL, Formisano F, Efficacy and safety of sildenafil in the treatment of severe pulmonary hypertension in patients with hemoglobinopathies. Hematologica. 2005;90(4):452–458.
   PubMed Web of Science ®Google Scholar
• Taher AT, Otrock ZK, Uthman I, Cappellini MD. Thalassemia and hypercoagulability. Blood Rev. 2008;22(5):283–292.
   PubMed Web of Science ®Google Scholar
• Giardina PJV, Forget BG. Thalassemia syndromes. In: Hoffman R, Benz EJ, Shattil SJ, Furie B, Silberstein LE, McGlave P, Heslop H, Eds. Hematology: Basic Principles and Practice, 5th ed. Philadelphia: Elsevier Churchill Livingstone. 2008:535–563.
   Google Scholar
• Patle NM, Tantia O, Sasmal PK, Khanna S, Sen BT. Laparoscopic splenectomy in patients of β thalassemia: Our experience. J Minim Access Surg. 2010;6(3):70–75.
   PubMedGoogle Scholar
• Brozovic M, Henthorn J. Investigation of abnormal haemoglobins and thalassaemia. In: Dacie JV, Lewis MS, Eds. Practical Haematology, 8th ed. London: Churchill Livingstone. 1995:249–286.
   Google Scholar
• Bain BJ, Gupta R. A-Z of Haematology, 1st ed. Malden: Blackwell. 2003;119–126.
   Google Scholar
• Revenant MC, Goudable J, Beaudonnet A, Mailliavin A, Pichot J, Monnet L. Determination of serum ferritin by one step immunoenzymoassay, and comparison of four liver-ferritin standards. Clin Chem. 1985;31(4):640–642.
   PubMedGoogle Scholar
• Kim AI, Saab S. Interpretation of laboratory tests for diagnosing viral hepatitis. Hosp Physician. 2004:15–19.
   Google Scholar
• World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser. 1994;843:1–129.
   PubMed Web of Science ®Google Scholar
• Schiller NB, Shah PM, Crawford M, Recommendations for quantitation of the left ventricle by two dimensional echocardiography: American Society of Echocardiography Committee on Standards Subcommitte. J Am Soc Echocardiogr. 1989;2(5):358–367.
   PubMedGoogle Scholar
• Lang RM, Bierig M, Devereux RB, Recommendations for chamber quantification. Eur J Echocardiogr. 2006;7(2):79–108.
   PubMed Web of Science ®Google Scholar
• Kurita A, Itoh H, Sato F, Ichibori Y, Yoshida A. Longitudinal fractional shortening and its relation to diastolic cardiac function. J Med Ultrason. 2008;35(3):113–118.
   PubMedGoogle Scholar
• Feigenbaum H. Echocardiographic evaluation of cardiac chambers. In: Feigenbaum H, Ed. Echocardiography, 5th ed. Philadelphia: Lea and Febiger. 1997:137–173.
   Google Scholar
• Lubien E, DeMaria A, Krishnaswamy P, Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings. Circulation. 2002;105(5):595–601.
   PubMed Web of Science ®Google Scholar
• Dabestani A, Mahan G, Gardin JM, Evaluation of pulmonary artery pressure and resistance by pulsed Dopplaer echocardiography. Am J Cardiol. 1987;59(6):662–668.
   PubMedGoogle Scholar
• Ware JE Jr, Kosinski M, Bayliss MS, McHorney CA, Rogers WH, Raczek A. Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the Medical Outcomes Study. Med Care. 1995;33(4 Suppl.):AS264–279.
   PubMed Web of Science ®Google Scholar
• Tavallaii SA, Fathi-Ashtiani A, Nasiri M, Assari S, Maleki P, Einollahi B. Correlation between sexual function and postrenal transplant quality of life: does gender matter? J Sex Med. 2007;4(6):1610–1618.
   PubMedGoogle Scholar
• Khedmat H, Karami GR, Pourfarziani V, Assari S, Rezailashkajani M, Naghizadeh MM. A logistic regression model for predicting health-related quality of life in kidney transplant recipients. Transplant Proc. 2007;39(4):917–922.
   PubMedGoogle Scholar
• Azarkeivan A, Hajibeigi B, Alavian SM, Lankaran MM, Assari S. Associates of poor physical and mental health-related quality of life in β thalassemia-major/intermedia. Journal of Research in Medical Sciences 2009;14(6):349–355.
   PubMed Web of Science ®Google Scholar
• Habib A, Kunzelmann C, Shamseddeen W, Zobairi F, Freyssinet JM, Taher A. Elevated levels of circulating procoagulant microparticles in patients with β-thalassemia intermedia. Hematologica. 2008;93(6):941–942.
   PubMed Web of Science ®Google Scholar
• Hafeez M, Aslam M, Ali A, Rashid Y, Jafri H. Regional and ethnic distribution of β thalassemia mutations and effect of consanguinity in patients referred for prenatal diagnosis. J Coll Physician Surg Pak. 2007;17(3):144–147.
   PubMed Web of Science ®Google Scholar
• Ayesh SK, Al-Sharef WA, Nassar SM, Thawabteh NA, Abu-Libdeh BY. Prenatal diagnosis of β-thalassemia in the West Bank and Gaza. Saudi Med J. 2005;26(11):1771–1776.
   PubMed Web of Science ®Google Scholar
• Arif F, Fayyaz J, Hamid A. Awareness among parents of children with thalassemia major. J Pak Med Assoc. 2008;58(11):621–624.
   PubMedGoogle Scholar
• De Sanctis V, Eleftheriou A, Malventura C. Prevalence of endocrine complications and short stature in patients with thalassemia major: a multicenter study by the Thalassemia International Federation (TIF). Pediatr Endocrinol Rev. 2004;2(Suppl. 2):249–255.
   PubMedGoogle Scholar
• Borgna-Pignatti C, Cappellini MD, De Stefano P, Survival and complications in thalassemia. Ann NY Acad Sci. 2005;1054:40–47.
   PubMed Web of Science ®Google Scholar
• Karamifar H, Karimi M, Amirhakimi GH, Badiei M. Endocrine functions in thalassemia intermedia. Int J Biomed Sci. 2006;2(3):236–240.
   PubMedGoogle Scholar
• Papadimas J,Goulis DG, Mandala E, β-Thalassemia and gonadal axis: a cross-sectional, clinical study in Greek population. Hormones (Athens). 2002;1(3):179–187.
   PubMedGoogle Scholar
• Aessopos A, Farmakis D, Tsironi M, Hemodynamic assessment of splenomegaly in β-thalassemia patients undergoing splenectomy. Ann Hematol. 2004;83(12):775–778.
   PubMedGoogle Scholar
• Aessopos A, Kati M, Farmakis D. Heart disease in thalassemia intermedia: a review of the underlying pathophysiology. Haematologica. 2007;92(5):658–665.
   PubMed Web of Science ®Google Scholar
• Rasekhi AR, Naderifar M, Bagheri MH, Radiofrequency ablation of the spleen in patients with thalassemia intermedia: a pilot study. AJR Am J Roentgenol. 2009;192(5):1425–1429.
   PubMedGoogle Scholar
• Terpos E, Voskaridou E. Treatment options for thalassemia patients with osteoporosis. Ann NY Acad Sci. 2010;1202:237–243.
   PubMed Web of Science ®Google Scholar
• Dresner-Pollack R, Rachmilewitz E, Blumenfeld A, Idelson M, Goldfarb AW. Bone mineral metabolism in adults with β-thalassaemia major and intermedia. Br J Haematol. 2000;111(3):902–907.
   PubMedGoogle Scholar
• Vogiatzi MG, Autio KA, Schneider R, Giardina PJV. Low bone mass in prepubertal children with thalassemia major: insights into the pathogenesis of low bone mass in thalassemia. J Pediatr Endocrinol Metab. 2004;17(10):1415–1421.
   PubMedGoogle Scholar
• Vogiatzi MG, Autio KA, Mait JE, Schneider R, Lesser M, Giardina PJV. Low bone mineral density in adolescents with thalassemia. Ann NY Acad Sci. 2005;1054:462–466.
   PubMed Web of Science ®Google Scholar
• Karimi M, Ghiam AF, Hashemi A, Alinejad S, Soweid M, Kashef S. Bone mineral density in β-thalassemia major and intermedia. Indian Pediatr. 2007;44(1):29–32.
   PubMedGoogle Scholar
• Voskaridou E, Terpos E. Pathogenesis and management of osteoporosis in thalassemia. Pediatr Endocrinol Rev. 2008;6(Suppl. 1):86–93.
   PubMedGoogle Scholar
• Voskaridou E, Terpos E. New insights into the pathophysiology and management of osteoporosis in patients with β-thalassaemia. Br J Haematol. 2004;127(2):127–139.
   PubMed Web of Science ®Google Scholar
• Gurevitch O, Slavin S. The hematological etiology of osteoporosis. Med Hypotheses. 2006;67(4):729–735.
   PubMed Web of Science ®Google Scholar
• Aessopos A, Farmakis D, Deftereos S, Thalassemia heart disease: a comparative evaluation of thalassemia major and thalassemia intermedia. Chest. 2005;127(5):1523–1530.
   PubMed Web of Science ®Google Scholar
• Aessopos A, Farmakis D, Deftereos S, Cardiovascular effects of splenomegaly and splenectomy in β-thalassemia. Ann Hematol. 2005;84(6):353–357.
   PubMed Web of Science ®Google Scholar
• Vaccari M, Crepaz R, Fortini M, Left ventricular remodeling, systolic function, and diastolic function in young adults with β-thalassemia intermedia: a Doppler echocardiography study. Chest. 2002;121(2):506–512.
   PubMed Web of Science ®Google Scholar
• Bosi G, Crepaz R, Gamberini MR, Left ventricular remodelling, and systolic and diastolic function in young adults with β-thalassemia major: a Doppler echocardiographic assessment and correlation with hematological data. Heart. 2003;89(7):762–766.
   PubMedGoogle Scholar
• Kremastinos DT, Tsiapras DP, Testsos GA, Rentoukas EI, Vretou HP, Toutouzas PK. Left ventricular diastolic Doppler characterstics in β-thalassemia major. Circulation. 1993;88(3):1127–1135.
   PubMed Web of Science ®Google Scholar
• Aessopos A, Farmakis D, Deftereos S, Thalassemia heart disease: a comparative evaluation of thalassemia major and thalassemia intermedia. Chest. 2005;127(5):1523–1530.
   PubMed Web of Science ®Google Scholar
• Tsomi K, Karagiorga-Lagana M, Karabatsos F, Arterial elastorrhexis in β-thalassemia intermedia, sickle cell thalassemia and hereditary sherocytosis. Eur J Haematol. 2001;67(3):135–141.
   PubMedGoogle Scholar
• Cappellini MD, Grespi E, Cassinerio E, Bignamini D, Fiorelli G. Coagulation and splenectomy: an overview. Ann NY Acad Sci. 2005;1054:317–324.
   PubMed Web of Science ®Google Scholar
• Moroni GA, Piacentini G, Terzoli S, Jean G, Masera G. Hepatitis B or non-A, non-B virus infection in multitransfused thalassaemic patients. Arch Dis Child. 1984;59(12):1127–1130.
   PubMedGoogle Scholar
• Ansar MM, Kooloobandi A. Prevalence of hepatitis C virus infection in thalassemia and hemodialysis patients in north Iran-Rasht. J Viral Hepat. 2002;9(5):390–392.
   PubMedGoogle Scholar
• El-Nanawy AA, El-Azzouni OF, Soliman AT, Amer AF, Demian RS, El-Sayed HM. Prevalence of hepatitis-C antibody seropositivity in healthy Egyptian children and four high risk groups. J Trop Pediatr. 1995;41(6);341–343.
   PubMedGoogle Scholar
• Cunningham MJ. Update on thalassemia: clinical care and complications. Pediatr Clin North Am. 2008;55(2):447–460.
   PubMed Web of Science ®Google Scholar
• Galanello R, Piras S, Barella S, Cholelithiasis and Gilbert’s syndrome in homozygous β-thalassaemia. Br J Haematol. 2001;115(4):926–928.
   PubMed Web of Science ®Google Scholar
• Nasr MR, Shaker M, Mahdy H, Hafez A. Gall bladder contractility in children with β-thalassaemia. East Mediterr Health J. 2009;15(2):315–321.
   PubMedGoogle Scholar
• Origa R, Galanello R, Perseu L, Cholelithiasis in thalassemia major. Eur J Haematol. 2009;82(1):22–25.
   PubMedGoogle Scholar
• Gamberini MR, Fortini M, De Scantis V, Gilli G, Testa MR. Diabetes mellitus and impaired glucose tolerance in thalassaemia major: incidence, prevalence, risk factors and survival in patients followed in the Ferrara Center. Pediatr Endocrinol Rev. 2004;2(Suppl. 2):285–291.
   PubMedGoogle Scholar
• Najafipour F, Aliasgarzadeh A, Aghamohamadzadeh N, A cross-sectional study of metabolic and endocrine complications in β-thalassemia major. Ann Saudi Med. 2008;28(5):361–366.
   PubMed Web of Science ®Google Scholar
• Bazrgar M, Peiravian F, Abedpour F, Karimi M. Causes for hospitalization and death in Iranian patients with β-thalassemia major. Pediatr Hematol Oncol. 2010; 28(2):134–139.
   PubMedGoogle Scholar
• Sumoza A, de Bisotti R, Sumoza D, Fairbanks V. Hydroxyurea (HU) for prevention of recurrent stroke in sickle cell anemia (SCA). Am J Hematol. 2002;71(3):161–165.
   PubMed Web of Science ®Google Scholar
• Ballas SK, Bauserman RL, McCarthy WF, Castro OL, Smith WR, Waclawiw MA. Hydroxyurea and acute painful crises in sickle cell anemia: effects on hospital length of stay and opioid utilization during hospitalization, outpatient acute care contacts, and at home. J Pain Symptom Manage. 2010; 40(6):870–882.
   PubMed Web of Science ®Google Scholar
• Dixit A, Chatterjee TC, Mishra P, Hydroxyurea in thalassemia intermedia – a promising therapy. Ann Hematol. 2005;84(7):441–446.
   PubMed Web of Science ®Google Scholar
• Rodgers GP, Saunthararajah Y. Advances in experimental treatment of β-thalassemia. Expert Opin Investig Drugs. 2001;10(5):925–934.
   PubMed Web of Science ®Google Scholar
• Baliga BS, Haynes J Jr, Obiako B, Mishra N. Combined effects of arginine and hdroxyurea on BFU-E derived colony growth and Hb F synthesis in erythroid progenitors isolated from sickle cell blood. Cell Mol Biol (Noisy-le-grand). 2010;56(Suppl.):OL1290–1298.
   PubMedGoogle Scholar
• Koren A, Levin C, Dgnay O, Response to hydroxyurea therapy in β-thalassemia. Am J Hematol. 2008;83(5):366–370.
   PubMed Web of Science ®Google Scholar
• Loukopoulos D, Vaskaridou E, Stamoulakatou A, Hydroxyurea therapy in thalassemia. Ann NY Acad Sci. 1998;850:120–128.
   PubMed Web of Science ®Google Scholar
• Bradi M, Pissard S, Abad MT, Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia. Transfusion. 2007;47(10):1830–1836.
   PubMedGoogle Scholar
• Yavariani M, Karimi M, Bakker E, Harteveld CL, Giordano PC. Response to hydroxyurea treatment in Iranian transfusion dependent β-thalassemia patients. Haematologica. 2004;89(10):1172–1178.
   PubMedGoogle Scholar
• Hajjar FM, Pearson HA. Pharmacologic treatment of thalassemia intermedia with hydroxyurea. J Pediatr. 1994;125(3):490–492.
   PubMed Web of Science ®Google Scholar
• Yesilipek MA, Hazar V, Yegin O. L-carnitine treatment in β-thalassemia major. Acta Hematol. 1998;100(3): 162–163.
   PubMedGoogle Scholar
• El-Beshlawy A, Ragab L, Fattah AA, Improvement of cardiac function in thalassemia major treated with L-carnitine. Acta Hematologica. 2004;111(3):143–148.
   PubMedGoogle Scholar
• Koliakos G, Papachristou F, Koussi A, Urine biochemical markers of early renal dysfunction are associated with iron overload in β-thalassaemia. Clin Lab Haematol. 2003;25(2):105–109.
   PubMedGoogle Scholar
• Ali D, Mehran K, Moghaddam AG. Comparative evaluation of renal findings in β-thalassemia major and intermedia. Saudi J Kidney Dis Transpl. 2008;19(2):206–209.
   PubMedGoogle Scholar
• Tantawy AA, Adly AA, Mahdy SA, Kamel GZ. Spinal cord compression and extramedullary hematopoiesis in young Egyptian β-thalassemia patients. Hemoglobin. 2009;33(6):448–462.
   PubMed Web of Science ®Google Scholar